Exploration of Effect Weight Loss Outcome Related to Factors After Treatment of Weight Loss (WRRFA).

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

The treatment for weight loss was more diverse due to the higher prevalence of obesity. In addition to weight loss medications, many patients seek bariatric surgery to treat obesity. Although bariatric surgery was the most effective way, the patients still get weight gain due to failure to control their lives. The failure weight loss is caused by complex risk factors, such as dietary habits, quality of life, physical inactivity, comorbidities remission rate, and more related to the failure weight loss factors. To explore weight gain factors, the study uses many questionnaires, including demographic parameter and exercise frequency survey, the WHOQOL-BREF assessment, The Bariatric Quality of Life Questionnaire (BQL), the Three-Factor Eating Questionnaire (TFEQ-R18), the Yale Food Addiction Scale version 2.0 (YFAS 2.0), and Depression Anxiety Stress Scales-21 (DASS-21). The investigators assess different factors like quality of life, food addiction, preferences, psychological status, and regular examination parameters to identify reasons for unsuccessful weight loss. The study aims to establish the model for the prediction of risk factors after treatment of weight loss so that the tools will help to manage the best weight control for the future.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 20
Maximum Age: 65
Healthy Volunteers: f
View:

• 6\. Signing the informed consent form for clinical trials.

Locations
Other Locations
Taiwan
Chung-Yen Chen
RECRUITING
Kaohsiung City
Contact Information
Primary
Chung-Yen Chen, MD.
drchenchungyen@gmail.com
886-9-75106259
Backup
Zhi-Han Sun, Bachelor
sunzhihan848@gmail.com
886-9-78519107
Time Frame
Start Date: 2024-06-27
Estimated Completion Date: 2028-12-31
Participants
Target number of participants: 900
Treatments
Surgical group
Bariatric surgery Participants underwent LSG, OAGB, SASI, and RYGB surgical treatment during the period from 2024 to 2028.
Non-Surgical group
Participants were treated with anti-obesity medications plus lifestyle intervention therapy Participants were treated with TFDA-approved anti-obesity medications (e.g. Saxenda, Contrave, etc.).
Related Therapeutic Areas
Sponsors
Leads: E-DA Hospital

This content was sourced from clinicaltrials.gov